Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10
about
Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10HIV-Host Interactions: Implications for Vaccine DesignStructural insights on the role of antibodies in HIV-1 vaccine and therapyStructure of an HIV-1-neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimerProgress in HIV-1 vaccine development.Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Redemption of autoreactive B cells.Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity.Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1Polyreactivity and autoreactivity among HIV-1 antibodies.HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design.Crystallographic Identification of Lipid as an Integral Component of the Epitope of HIV Broadly Neutralizing Antibody 4E10.Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineagesFunctional Versatility of AGY Serine Codons in Immunoglobulin Variable Region Genes.Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies.HIV Diagnosis and Treatment through Advanced Technologies.Structural and biochemical insights into the V/I505T mutation found in the EIAV gp45 vaccine strain.Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes.Broadly neutralizing antibodies and the promise of universal vaccines: where are we now?Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies.New approaches to HIV vaccine development.Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals.Genetic and structural analyses of affinity maturation in the humoral response to HIV-1.Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development.Host controls of HIV broadly neutralizing antibody development.Potent and broad HIV-neutralizing antibodies in memory B cells and plasma.Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies.What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling.HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism.Uncommon structural motifs dominate the antigen binding site in human autoantibodies reactive with basement membrane collagen.Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses.Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations.Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity.
P2860
Q21089590-D2785785-0E0A-4940-9F2D-C3CC22365ACEQ26765966-2680E2EF-E0EE-445B-928B-C8A84C1109E1Q26829461-EE3E61F5-3D96-4D72-80DA-F7F9137FEB5DQ27681501-C418F9B4-77C5-44F8-BD92-5758BF77B714Q27693849-BB6739FD-207F-4244-83FA-C626C185BB9AQ30234773-06FEEFCC-3CE9-41CC-B7BB-C13EADB40BEEQ33835034-9FDF7FF3-4F0D-4116-AD4E-00F313927590Q33835200-A2768691-8E69-40D1-BF62-E83DBA20A44BQ34022578-014052C1-A84E-40B4-B494-D8918D3BFE76Q34396912-A15A0630-89C3-43FA-8590-536C7181F14BQ34992787-97E16551-5472-4B21-AB2F-747721B0E981Q35172770-13DCBE31-142E-4CFB-A0F3-013C89977D86Q36287539-B1BD85AE-4FBC-4356-B42B-29AED82FC695Q36485204-F3AF3CF3-56C3-41A8-A26C-4752D799BA6CQ36627503-C0CA4CAD-9582-4E42-8BAD-775C8A0E9AB6Q37171251-6F5D0C24-D7F2-4649-8B7D-CFA85879A0F9Q37221575-52EF5E00-B358-486B-85FF-B15C06272A47Q37427477-2BF0E9C4-FE9B-484C-AD6E-0A058C000691Q37607358-176D395D-4A29-471D-9AA4-BB9AF0CC473AQ37683120-3AB88BDF-F947-4DD5-A394-E8DCD527B099Q37720380-285FFFDF-AD10-45D4-A594-38DFC9F60F32Q37730206-81CCF706-FA66-4141-8E38-291CAF61D981Q38171571-FCF1F49D-DDC2-4C52-A70F-6A7544749766Q38220506-BD51FF18-899C-4D4C-8AC2-4358F40CC986Q38521826-55B9B5FE-4F7E-4AFA-BEC8-87CFEF224430Q38986943-90FD8573-7A20-4B96-82FF-481FD7222870Q38992744-F854AC30-32F9-4B48-8542-E17DA8F2E95AQ39108735-7565042F-D836-4965-B8EB-7AB2B42797D1Q39108751-30691030-BDF7-4684-AB30-48B36EB589E4Q39108769-C1B0E6B6-F356-4B77-B72B-7E920FAA0743Q40092127-2D705C54-36AC-4361-B0F4-5DA26E24B7F8Q40103798-A4C900B9-ABBE-400E-9FED-26E019141856Q40166335-72FE6E5A-55CA-4BF1-B8D2-4E7EDF00B6C8Q40449984-865CFB5C-1112-491F-8549-CE0B71A6DCFBQ42051255-6B59B8C6-242B-4A4B-8456-F514CDA8E3AEQ42278743-EB2DA6DD-D789-42C4-BDDC-D13F2F2A475CQ47118310-057B0EBE-D858-4D55-BF52-12BB8E25DC29Q55265892-050F76A1-D3A1-47E4-A425-202CA09215A8
P2860
Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Common tolerance mechanisms, b ...... lizing antibodies 2F5 and 4E10
@en
Common tolerance mechanisms, b ...... izing antibodies 2F5 and 4E10.
@nl
type
label
Common tolerance mechanisms, b ...... lizing antibodies 2F5 and 4E10
@en
Common tolerance mechanisms, b ...... izing antibodies 2F5 and 4E10.
@nl
prefLabel
Common tolerance mechanisms, b ...... lizing antibodies 2F5 and 4E10
@en
Common tolerance mechanisms, b ...... izing antibodies 2F5 and 4E10.
@nl
P2093
P2860
P356
P1476
Common tolerance mechanisms, b ...... lizing antibodies 2F5 and 4E10
@en
P2093
Amanda Newman
Hilary Bouton-Verville
Jinsong Zhang
Kwan-Ki Hwang
Laurent Verkoczy
Shi-Mao Xia
Ying-Bin Ouyang
P2860
P304
P356
10.4049/JIMMUNOL.1300770
P407
P577
2013-07-03T00:00:00Z